Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a ...

The patent is part of Clearmind’s exclusive worldwide licensing agreement with Yissum to develop, research, manufacture, market and commercialize products derived from a patent-pending synthesis of ...